Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and other diseases with unmet medical needs [1] - The Combined Shareholders' Meeting held on December 11, 2024, resulted in the adoption of all resolutions except for resolution 59, which was negatively recommended by the Board of Directors [1][2] - The company’s lead product candidate, lanifibranor, is currently in a pivotal phase 3 clinical trial, NATiV3, targeting adult patients with MASH/NASH [6] Shareholder Meeting Results - Total number of shares with voting rights: 86,962,703 [1] - Quorum for the meeting was 79.738% [1] - Resolution 1 received 99.58% approval, while resolution 59 was rejected with 90.24% against [2][5] Voting Results - Ordinary resolutions were largely adopted with high approval rates, such as resolution 1 (99.58%) and resolution 2 (99.58%) [2] - Extraordinary resolutions also saw significant support, with resolution 5 receiving 99.96% approval [3] - The voting results indicate strong shareholder confidence in the company's direction and governance [2][3] Company Overview - Inventiva has a pipeline that includes one clinical candidate and two preclinical programs, with a focus on lanifibranor and a review of odiparcil's development options [6] - The company employs approximately 90 people with expertise in various scientific fields and owns a library of around 240,000 pharmacologically relevant molecules [6] - Inventiva is publicly listed on Euronext Paris and Nasdaq, indicating its commitment to transparency and regulatory compliance [6]